1329643-44-8
1329643-44-8
Chemical Structure
(S)-(+)-Ibuprofen-d3
Synonym(s): (S)-Ibuprofen d3
- CAS No.: 1329643-44-8
- Formula:C13H15D3O2
- Molecular Weight:209.30
IUPAC Name: (S)-2-(4-isobutylphenyl)propanoic-3,3,3-d3 acid
InChIKey: HEFNNWSXXWATRW-PCXQMPHHSA-N
SMILES: OC([C@H](C1=CC=C(CC(C)C)C=C1)C([2H])([2H])[2H])=O
Biological Activity: (S)-(+)-Ibuprofen-d3 is a deuterium labeled (S)-(+)-Ibuprofen. (S)-(+)-Ibuprofen is the S(+)-enantiomer of Ibuprofen that inhibits COX-1 and COX-2 activity with IC50s of 2.1 μM and 1.6 μM. (S)-(+)-Ibuprofen has analgesic, antiinflammatory and antipyretic effects[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(S)-(+)-Ibuprofen-d3 | 99.96% | (S)-(+)-Ibuprofen-d3 is a deuterium labeled (S)-(+)-Ibuprofen. (S)-(+)-Ibuprofen is the S(+)-enantiomer of Ibuprofen that inhibits COX-1 and COX-2 activity with IC50s of 2.1 μM and 1.6 μM. (S)-(+)-Ibuprofen has analgesic, antiinflammatory and antipyretic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-(+)-Ibuprofen (Standard) | 99.87% | (S)-(+)-Ibuprofen (Standard) is the analytical standard of (S)-(+)-Ibuprofen. This product is intended for research and analytical applications. (S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-(+)-Ibuprofen | 99.95% | (S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Evans AM, et al. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 2001 Nov;20 Suppl 1:S9-14. [Content Brief]
- [2]. Xu HR, et al. The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects. Pharm Biol. 2010 Aug;48(8):947-52. [Content Brief]
